TrueCAGR

Laurus Labs Limited

NSE: LAURUSLABSBSE: 540222ISIN INE947Q01028Face value ₹2consolidated
₹2,295
−0.30% · 2026-11-20 · 52-wk ₹945–₹2,450
Source: BSE filings · Financials to FY2026 · 8 years of history · Data last updated: results filed 29 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.

Net profit growth+148.4%Revenue growth+22.7%

Importance 72 / 95 · growth

WatchTalking point

Stock has run ahead of the business

Over 5 years the stock returned 36.6% a year while profit shrank 2.0% a year.

Net profit−2.0%/yrShare price36.6%/yr

Importance 64 / 95 · business vs stock

WatchTalking point

Volatile earnings

Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.

Importance 58 / 95 · growth

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹1.24 L cr
FY2026 revenue
₹6,813 cr
FY2026 net profit
₹890 cr
Net worth
₹5,431 cr
Total debt
₹2,397 cr
EPS (basic)
₹16.47
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 16.8% a year over 7 years, from ₹2,292 cr in FY2019 to ₹6,813 cr in FY2026. Net profit grew 37.9% a year over the same period.

Revenue & net profit — FY19 to FY26₹ crore · consolidated
₹'000 cr02457011REVENUENET PROFIT2k94FY193k255FY205k984FY215k832FY226k793FY235k162FY246k358FY257k890FY26
RevenueNet profit
Strength

Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+16.8%over 7 years (FY19–FY26)
Revenue growth
+22.7%vs last year
Net profit growth
+148.4%vs last year
Change in net profit since FY19
+849%

Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.

Over 7 years profit compounded at 37.9% a year while revenue compounded at 16.8% a year — though FY2021 saw a one-off step-change of 285% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Revenue compounded at 16.8% a year over 7 years (₹2,292 → ₹6,813) — though FY2021 saw a one-off step-change of 70% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Net profit rose 148.4% to ₹890 — but FY2025 was a depressed ₹358 (vs a ~₹524 historical norm), so this is a recovery. Profit has compounded 37.9% a year over 7 years.

Revenue grew 22.7% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,206 cr (up 33.4% on the same quarter last year) and net profit ₹436 cr (up 124%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Strength

Q2 FY27 net profit was ₹436 cr, up 124.3% from ₹194 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Strength

Q2 FY27 revenue was ₹2,206 cr, up 33.4% from ₹1,653 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Strength

Q2 FY27 net profit grew 124.3% while revenue grew 33.4% vs the same quarter last year — a gap of 90.8 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01223001REVENUENET PROFIT1k93Q3 '252k233Q4 '252k162Q1 '262k194Q2 '262k252Q3 '262k282Q4 '262k362Q1 '272k436Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY251,415+18.4%93+298.2%6.6%
Q4 FY251,720+19.5%233+210.3%13.5%
Q1 FY261,570+31.4%162+1175.1%10.3%
Q2 FY261,653+35.1%194+874.9%11.8%
Q3 FY261,778+25.7%252+171.0%14.2%
Q4 FY261,812+5.3%282+21.2%15.6%
Q1 FY272,026+29.1%362+123.9%17.9%
Q2 FY272,206+33.4%436+124.3%19.8%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹7,823 crTTM
EBITDA
₹2,421 crTTM
EBIT
₹1,927 crTTM
PBT
₹1,761 crTTM
Net profit
₹1,332 crTTM

C. Corporate actions

6 Nov 2026DividendInterim Dividend - Rs. - 1.0000 — ₹1.00/share
8 May 2026DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
31 Oct 2025DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
9 May 2025DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
6 Nov 2024DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
8 May 2024DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
2 Nov 2023DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
10 May 2023DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
3 Nov 2022DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
10 May 2022DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
17 Nov 2021DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
11 May 2021DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
8 Feb 2021DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
10 Nov 2020DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
29 Sept 2020Stock splitStock Split From Rs.10/- to Rs.2/- — 10:2
1 Jul 2020DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
23 Mar 2020DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
3 Jul 2019DividendDividend - Rs. - 1.5000 — ₹1.50/share
28 Jun 2018DividendDividend - Rs. - 1.5000 — ₹1.50/share
6 Jul 2017DividendDividend - Rs. - 1.5000 — ₹1.50/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 26.9% in FY2026, against 16.2% in FY2019. ROE was 17.7% and ROCE 17.9% in FY2026.

Margins — FY19 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%35%26.9%13.0%FY19FY20FY21FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

EBITDA margin improved from 20.4% to 26.9% of revenue.

Rule MARGIN_EXPANDED_YOY

EBITDA margin now
26.9%
8-year range
15.9–32.7%
ROE FY2026
17.7%
ROCE FY2026
17.9%

ROE rose from 8.2% to 17.7% — but FY2025 was a depressed year, so this is a rebound rather than a step-up.

EBITDA margin has ranged from 15.9% to 32.7% over 7 years and sits at 26.9% now.

Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.44x in FY2026, against 0.61x in FY2019; interest coverage 7.92x. Operating cash flow was 1.82x net profit.

Net worth — FY19 to FY26₹ crore · consolidated
₹'000 cr02462kFY192kFY203kFY213kFY224kFY234kFY245kFY255kFY26
Net worth (shareholders' funds)
Strength

Operating cash flow has matched or exceeded reported profit in 5 of the last 6 profit-making years (latest 1.82×).

Rule CFO_CONSISTENTLY_EXCEEDS_PAT

Operating cash flow vs net profit₹ crore · FY21–FY26
0k1k1k2k733984FY21911832FY22994793FY23666162FY24602358FY252k890FY26
Operating cash flowNet profit
Total debt
₹2,397 cr
Operating cash flow ÷ net profit
1.82×FY2026
Free cash flow
₹560 cr
Current ratio
1.33×

Net worth compounded at 19.5% a year over 7 years (₹1,558 → ₹5,431) — though FY2021 saw a one-off step-change of 47% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Free cash flow has been positive in 5 of the last 6 years.

Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 3 of 12 on return on equity and 8 of 12 on EBITDA margin. Its P/E of 93.0 compares with a peer median of 45.3.

Ranked against 12 pharmaceuticals (FY2026, consolidated).

Revenue growth

LAURUSLABS · 3rd of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

LAURUSLABS · 8th of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

LAURUSLABS · 3rd of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

LAURUSLABS · 11th of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
Context

Trades at 93.00× earnings — 105% above the pharmaceuticals median of 45.29×.

Rule PE_ABOVE_PEERS

P / E
93.0×TTM to Sept 26
P / B
22.8×latest book
P / S
15.8×TTM sales
Earnings yield
1.1%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 139.2× · P/S 18.0× · ROE 17.7%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.

Section 09 · The stock

How has the stock performed?

The share price is up 132% over 1 year, up 514% over 3 years (83.1% a year) and up 376% over 5 years (36.6% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 6.3% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k4k₹2,2952020202120222023202420252026
Watch

Over 5 years the stock returned 36.6% a year while profit shrank 2.0% a year.

Rule STOCK_RAN_AHEAD

Business vs stock — 5-year compound annual rate
Net profit-2.0%/yrShare price36.6%/yr
1-year return
+132.5%
3-year return
+514.1%
5-year return
+376.1%
From 52-wk high
−6.3%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹2,117
vs 200-day avg
Above₹1,541
RSI (14)
54.2neutral
MACD histogram
-16.7
From 52-wk high
−6.3%
From 52-wk low
+142.9%
30-day volatility
45.9%ann.
6-month return
+68.6%
RSI (14) · 0–10054.2 — neutral
0305070100OVERSOLDOVERBOUGHT54.2
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Stock has run ahead of the business
    Over 5 years the stock returned 36.6% a year while profit shrank 2.0% a year.
    STOCK_RAN_AHEAD · conviction 64
  • Watch
    Volatile earnings
    Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.
    EARNINGS_VOLATILE · conviction 58
  • Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY19FY20FY21FY22FY23FY24FY25FY26
Revenue2,2922,8324,8144,9366,0415,0415,5546,813
Total income2,3082,8384,8374,9516,0475,0675,6296,868
EBITDA3725701,5741,4381,5988041,1301,833
Profit before tax1202941,3011,0841,1092364841,182
Net profit94255984832793162358890
EPS (₹)8.823.918.415.414.73.06.716.5
Net worth1,5581,7702,6013,3594,0494,1164,6035,431
Total debt9439561,3151,7321,9722,5072,6932,397
Operating cash flow——7339119946666021,624
Free cash flow——44346−1061560
Key ratios — consolidated
RatioFY19FY20FY21FY22FY23FY24FY25FY26
Growth
Revenue growth YoY—23.670.02.522.4-16.610.222.7
Profit growth YoY—172.3285.4-15.4-4.7-79.5120.8148.4
Profitability
EBITDA margin %16.220.132.729.126.515.920.426.9
Net margin %4.19.020.316.813.13.26.413.0
Return on equity %6.015.345.027.921.44.08.217.7
Return on capital %8.314.741.226.322.96.610.117.9
Leverage & cash
Debt to equity0.610.540.510.520.490.610.590.44
Cash flow ÷ profit——0.751.091.254.101.681.82
Current ratio1.031.071.251.251.421.231.221.33
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.